Unity Biotechnology, Inc.

NasdaqGS UBX

Unity Biotechnology, Inc. Dividend Yield on February 06, 2025

Unity Biotechnology, Inc. Dividend Yield is NA on February 06, 2025, a NA change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Unity Biotechnology, Inc. 52-week high Dividend Yield is 0.00% on January 16, 2025, which is NA below the current Dividend Yield.
Unity Biotechnology, Inc. 52-week low Dividend Yield is 0.00% on January 16, 2025, which is NA below the current Dividend Yield.
Unity Biotechnology, Inc. average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqGS: UBX

Unity Biotechnology, Inc.

CEO	Dr. Anirvan Ghosh Ph.D.
IPO Date	May 3, 2018
Location	United States
Headquarters	285 East Grand Avenue
Employees	19
Sector	Consumer Discretionary
Industries Eyewear Biotechnology Clinical Trials Drugstores & Retail Pharmacies Pharmaceuticals

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Key trends

Past 5 years